×
Eiger BioPharmaceuticals Net Profit Margin 2012-2023 | EIGRQ
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Eiger BioPharmaceuticals net profit margin from 2012 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Eiger BioPharmaceuticals Net Profit Margin 2012-2023 | EIGRQ
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Eiger BioPharmaceuticals net profit margin from 2012 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.6B
Regeneron Pharmaceuticals (REGN)
$127.1B
Vertex Pharmaceuticals (VRTX)
$125.3B
Gilead Sciences (GILD)
$103.1B
Bristol Myers Squibb (BMY)
$99.6B
CSL (CSLLY)
$97.7B
GSK (GSK)
$89.1B
Alnylam Pharmaceuticals (ALNY)
$34.1B
Argenex SE (ARGX)
$32.2B
BioNTech SE (BNTX)
$29.3B
Biogen (BIIB)
$28.5B
Moderna (MRNA)
$26.2B
Illumina (ILMN)
$20.6B
BeiGene (BGNE)
$19.3B
Genmab (GMAB)
$17.8B
BioMarin Pharmaceutical (BMRN)
$16.1B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
Incyte (INCY)
$12.2B
Exact Sciences (EXAS)
$12.1B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.8B
QIAGEN (QGEN)
$10.6B
Legend Biotech (LEGN)
$9.2B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.8B
Intra-Cellular Therapies (ITCI)
$8B
Halozyme Therapeutics (HALO)
$7.9B
Repligen (RGEN)
$7.8B
Exelixis (EXEL)
$7.5B